本文已被：浏览 141次 下载 94次
投稿时间：2024-09-21 网络发布日期：2025-11-26
投稿时间：2024-09-21 网络发布日期：2025-11-26
中文摘要: 目的 探讨肺维康颗粒对间质性肺炎（IP）的疗效和对肺纤维化的影响及与白细胞介素（IL）-17信号通路的关系。方法 选取 2023 年 1 月至 12 月在某三级甲等医院就诊的 120 例 IP 患者（均为特发性间质性肺炎患者），随机分为试验组和对照组，每组60例。试验组口服吉林长白山药业生产的肺维康颗粒5 g/次，2次/d；对照组服用CilagAG生产的安慰剂5 g/次，2次/d，加醋酸泼尼松口服治疗，1次/d。两组疗程均为12周。评估指标包括血清IL-17、纤维化标志物［α-平滑肌肌动蛋白（α-SMA）、胶原蛋白（collagen）I］和其他炎症因子［肿瘤坏死因子（TNF）-α、IL-6、转化生长因子（TGF）-β］水平，以及肺功能、氧合指数［即动脉氧分压（PaO2）/吸入氧浓度（FiO2）］、高分辨率CT肺组织水肿评分。结果 治疗12周后，试验组血清IL-17水平显著下降，并显著低于对照组［（32.15±8.94）pg/mL vs（50.21±11.78）pg/mL，t=9.94，P＜0.01］；血清α-SMA、collagen I、TNF-α、IL-6、TGF-β水平均降低，且均低于对照组（P＜0.05）；肺组织水肿评分降低，且低于对照组［（1.24±0.53）vs（2.05±0.55），t=7.79，P＜0.01］。治疗 12 周后与对照组比较，试验组 FEV1、FVC、FEV1/FVC 以及氧合指数［（297.45±45.32）vs（252.12±50.45），t=5.35，P＜0.01］均更高。试验组不良反应发生率21.67%，对照组23.33%，两组差异无统计学意义（χ2=0.05，P>0.05）。结论 肺维康颗粒可改善IP患者的肺功能，降低纤维化标志物和炎症因子水平，改善氧合指数和肺组织水肿，具有良好的疗效和安全性，其可能通过调控IL-17信号通路发挥作用。
Abstract:Objective To investigate the treatment effect of Feiweikang Granule on interstitial pneumonia（IP）treating and pulmonary fibrosis，and its relationship with the interleukin（IL）-17 signaling pathway. Methods One hundred and twenty patients with IP（all patients with idiopathic interstitial pneumonia）who attended a tertiary-level A hospital from January to December 2023 were selected and randomly divided into a test group and a control group，with 60 cases in each group. The test group was orally treated with Feiweikang Granules（produced by Jilin Changbaishan Pharmaceuticals）5 g a time，twice a day，while the control group was treated with placebo（produced by Cilag AG）5 g a time，twice a day，plus prednisone acetate orally once a day. The treatment course for both groups was 12 weeks. The evaluation indicators included serum IL-17，fibrosis markers［α-smooth muscle actin（α-SMA），collagen I］and other inflammatory factors［tumor necrosis factor（TNF）-α，IL-6，transforming growth factor（TGF）-β］levels，as well as lung function，oxygenation index［partial pressure of arterial oxygen（PaO2）/inhaled oxygen concentration（FiO2）］，and high-resolution CT lung tissue edema score. Results After 12 weeks of treatment，in the test group，serum IL-17 level decreased significantly and was significantly lower than that in the control group［（32.15±8.94）pg/mL vs（50.21±11.78）pg/mL，t=9.94，P<0.01］；serum α-SMA，collagen I，TNF-α，IL-6，and TGF-β levels were reduced，and all of
them were lower than those in the control group（P < 0.05）；lung tissue edema score was reduced and was lower than that in the control group［（1.24±0.53）vs（2.05±0.55），t=7.79，P<0.01］. FEV1，FVC，FEV1/FVC，and oxygenation index［（297.45±45.32）vs（252.12±50.45），t=5.35，P<0.01］were higher in the test group compared to the control group after 12 weeks of treatment. The incidence of adverse reactions showed no statistically significant difference between the test group and the control group（21.67%vs 23.33%，χ2=0.05，P>0.05）. Conclusion Feiweikang Granules can improve lung function of IP patients，reduce the levels of fibrosis markers and inflammatory factors，and improve oxygenation index and lung tissue edema，with good efficacy and safety，which may play a role by regulating IL- 17 signaling pathway.
keywords: Feiweikang Granules Interstitial pneumonia Interleukin⁃17 Signaling pathway Pulmonary fibrosis Clinical efficacy
文章编号： 中图分类号：R563.1+3 R259 文献标志码：B
基金项目:国家自然科学基金资助项目（82104799）
附件
| Author Name | Affiliation |
| WANG Guijuan*，WANG Xiuyun，WANG Jianyun，CUI Nini，ZHU Xue | *Department of Respiratory Medicine,Qingdao Municipal Hospital,Qingdao,Shandong 266011,China |
引用文本：
王闺娟，王秀云，王建芸，崔尼尼.肺维康颗粒治疗间质性肺炎的效果及对肺纤维化的影响[J].中国临床研究,2025,38(11):1761-1765.
王闺娟，王秀云，王建芸，崔尼尼.肺维康颗粒治疗间质性肺炎的效果及对肺纤维化的影响[J].中国临床研究,2025,38(11):1761-1765.